JB/PUT/GILEAD SCIENCES/90/0.05/20.09.24 Stock

GILGJB

CH1311831056

Market Closed - Bid/Ask 11:20:00 2024-06-04 am EDT			After market 11:15:00 am
1.19 ^CHF	-0.83%		1.195	+0.42%

Current month	-3.25%
1 month	+2.59%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart JB/PUT/GILEAD SCIENCES/90/0.05/20.09.24

Latest news about GILEAD SCIENCES, INC.

Combination therapy may hold potential for severe viral hepatitis	11:01am	AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	10:21am	AQ
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	08:23am	MT
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	04:31am	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-04	1.19	-0.83%
24-06-03	1.2	-2.44%
24-05-30	1.23	-0.81%
24-05-29	1.24	+5.98%
24-05-28	1.17	+2.63%

Delayed Quote Swiss Exchange

Last update June 04, 2024 at 11:20 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	GILEAD SCIENCES, INC.
Issuer	Bank Julius Bär
	GILGJB
ISIN	CH1311831056
Date issued	2024-01-09
Strike	90 $
Maturity	2024-09-20 (106 Days)
Parity	20 : 1
Emission price	0.43 CHF
Emission volume	N/A
Settlement	cash
Currency	CHF

Technical Indicators

Highest since issue	1.24 CHF
Lowest since issue	0.36 CHF
Spread	0.01 CHF
Spread %	0.83%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

63.88 USD

Average target price

82.7 USD

Spread / Average Target

+29.46%

Consensus